DMDespoina Manousaki

Despoina Manousaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Despoina Manousaki has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Causal Role of Adiponectin in Type 2 Diabetes across Ages and Sexes - An Observational and Mendelian Randomization Study

    by Samya Mavrikakis Legault, Isabel Gamache, Wiame Belbellaj, Basile Jumentier, John Eric Hamilton, Alexandre Matboui, Despoina Manousaki

  • Development and application of type 1 diabetes polygenic scores across diverse populations

    by Despoina Manousaki, Dominika A. Michalek, Hui-Qi Qu, Lauric A. Ferrat, Aaron J. Deutsch


  • Open Access

    Nature vs nurture of glucose homeostasis trajectories in children from the ALSPAC study

    by Isabel Gamache, Kaossarath Fagbemi, Soren Harnois-Leblanc, Celia M. T. Greenwood, Mélanie Henderson, Andrea Van Hulst, Nicholas J. Timpson, Despoina Manousaki

    Aims/hypothesis: Dysglycaemia in youth results from complex interactions between genetic and environmental factors, yet their individual and combined contributions remain unclear. We aimed to: (1) evaluate the predictive performance of polygenic risk scores (PRSs) for glycaemic traits from childhood to early adulthood; (2) identify gene–environment interactions shaping glucose homeostasis trajectories; and (3) explore underlying mechanisms using pathway-specific PRSs. Methods: Data from 8783 participants (aged 7–24 years) from the Avon Longitudinal Study of Parents and Children (ALSPAC) were used to compute 12 PRSs for type 2 diabetes, fasting glucose, insulin and BMI. Glycaemic outcomes, including insulin resistance, prediabetes (impaired fasting glucose) and type 2 diabetes, were assessed using fasting glucose and insulin (ages 7, 15, 18 and 24 years) and HbA 1c (age 9 years). We evaluated whether PRSs could distinguish between transient (resolved by adulthood) and persistent glycaemic abnormalities using multinomial regression. We performed univariate and multivariate regressions, incorporating environmental factors (lifestyle, diet and maternal characteristics), and evaluated model performance using R 2 and AUC. We tested interactions between PRS quintiles and environmental factors and explored pathophysiological mechanisms using pathway-specific PRSs. Results: Prediabetes prevalence was up to 24% at age 24 years. PRS-enhanced models outperformed those using environmental factors alone (e.g. AUC for dysglycaemia at age 15 improved by 0.12, reaching 0.78). Fasting glucose PRS showed moderate ability to differentiate transient from persistent prediabetes (AUC=0.70). Gene–environment analyses revealed that high genetic risk combined with increased screen time or younger maternal age increased insulin resistance risk. Physical activity and health awareness attenuated this risk. Pathway analyses indicated insulin secretion as a key mechanism earlier in life, with insulin resistance emerging later. Conclusions/interpretation: Genes interact with environment to define glucose homeostasis in youth, highlighting modifiable factors as actionable targets for early prevention.


  • Open Access

    Development and validation of a trans-ancestry polygenic risk score for type 1 diabetes

    by Basile Jumentier, Hui-Qi Qu, Tianyuan Lu, Kai Liu, Erica L. Kleinbrink, Kathleen Klein, Wiame Belbellaj, Isabel Gamache, Lauric Ferrat, Guillaume Butler-Laporte, et al.

    Aims/hypothesis The high heritability of type 1 diabetes has enabled the development of polygenic risk scores (PRSs) as disease risk screening tools. PRSs can identify individuals at the highest genetic risk in a population, who can benefit from autoantibody and metabolic surveillance, to avoid ketoacidosis at diagnosis and to access preventive therapies. However, PRSs for type 1 diabetes developed from European data perform less well in non-European ancestries. We aimed to develop a PRS with comparable performance among different ancestries. Methods Using the PRS-CSx method, and data from large European, East Asian, African American and Hispanic type 1 diabetes genome-wide association studies (Ntotal_cases=29,469), we developed a trans-ancestry PRS (TA-PS), combining a non-HLA component incorporating over a million variants with the HLA component of a published European PRS (GRS2x). We tested the performance of the PRS using area under the receiver operating curve (AUROC), sensitivity and specificity in a multi-ancestry type 1 diabetes case–control cohort (Ntotal=4657; Nnon-European=556) from Montreal, Canada. We validated our results in two independent type 1 diabetes case–control cohorts (Children's Hospital of Philadelphia, Center for Applied Genomics [CHOP-CAG] and Genetic Risk Assessment for Chinese Eaglet-T1D [GRACE]) and two population-based cohorts (All of Us and UK Biobank). Results In the multi-ancestry Montreal-based cohort, TA-PS showed an AUROC of 0.89 which was significantly higher than the respective measure obtained with GRS2x in the same population (AUROC of 0.85). We obtained better overall sensitivity at the 90th percentile cut-off using TA-PS (0.71 in Europeans, 0.77 in South Asians), compared with sensitivity of 0.32 in African Americans and 0.56 in Europeans using GRS2x. The specificity obtained using TA-PS was slightly lower than that of GRS2x, albeit still acceptable (≥0.83 across all ancestries). These results were validated in the four independent cohorts. Conclusions/interpretation We developed a trans-ancestry PRS that outperformed the European-based GRS2x. Importantly, TA-PS provides a comparable prediction in various ancestries, which supports its use in population-wide screening programmes. Graphical Abstract


  • Open Access

    Proteome-wide mendelian randomization reveals circulating proteins causally associated with childhood body mass index

    by Raphael Avocegamou, Basile Jumentier, Kaossarath Fagbemi, Nahid Yazdanpanah, Mojgan Yazdanpanah, Isabel Gamache, Despoina Manousaki

    Childhood obesity is a major public health problem, affecting one in 5 youths. We aimed to characterize biomarkers for pediatric obesity among circulating proteins using Mendelian randomization (MR). We utilized genome-wide significant cis-protein quantitative trait loci (pQTL) from three large adult proteomic GWAS (N total>58,000) and a small childhood proteomic GWAS (N=2,147) as genetic instruments for circulating protein levels. Using two-sample Mendelian randomization, we estimated causal effects of the circulating proteins on childhood body mass index (BMI) in a European GWAS of 39,620 children. MR Wald ratios were calculated to estimate the causal effect of each protein on childhood BMI. Sensitivity analyses testing the MR assumptions included colocalization and phenome-wide association studies (PheWAS). Replication was conducted using independent GWAS datasets, complemented by reverse MR and tissue enrichment analyses. Among 535 tested proteins, three colocalized and demonstrated decreasing effects on BMI per standard deviation increase in their level: endoglin (ENG; MR beta: -0.07, 95% CI [-0.10, -0.04], P=4.4×10⁻ 5 ), fatty acid binding protein 4 (FABP4; MR beta: -0.33, 95% CI [-0.50, -0.16], P=1.3×10⁻ 4 ), and cell adhesion molecule 1 (CADMI1; MR beta: -0.26, 95% CI [-0.37, -0.15], P=5.45×10⁻ 5 ). All three proteins showed evidence of colocalization (posterior probability >75%) and were identified using adult proteomic GWAS, given a limited statistical power using the pediatric proteomic GWAS data. Reverse causation was identified for FABP4, suggesting a compensatory mechanism. In conclusion, we identified three circulating proteins as potential blood biomarkers or drug targets for pediatric obesity, warranting further functional validation to elucidate biological mechanisms and assess therapeutic potential.


  • Open Access

    Association of Vitamins and Minerals with Type 1 Diabetes Risk: A Mendelian Randomization Study

    by Lucia Shi, Wiame Belbellaj, Despoina Manousaki

    Background/Objectives: Previous studies suggest that nutrient deficiencies can alter immune responses in animals. However, the impact of micronutrients on autoimmune diseases like type 1 diabetes (T1D) in humans remains unclear since the described associations are based on observational data and they cannot establish causality. This study aims to examine the causal relationship between various micronutrients and T1D using Mendelian randomization (MR). Methods: We performed a two-sample MR analysis using genetic variants from genome-wide association studies (GWASs) of 17 micronutrients as instrumental variables (IVs). We analyzed T1D GWAS datasets of European (18,942 cases/520,580controls), multi-ancestry (25,717 cases/583,311 controls), Latin American/Hispanic (2295 cases/55,134 controls), African American/Afro-Caribbean (6451 cases/109,410 controls), and East Asian (1219 cases/132,032 controls) ancestries. We applied the inverse variance weighted (IVW) method in our main analysis, and additional MR estimators (MR-Egger, weighted median, weighted mode, MR-PRESSO) to address pleiotropy, and the Steiger test to test directionality in sensitivity analyses. Results: Following Bonferroni correction (p < 0.05/17), we found positive association between potassium levels and T1D risk (OR = 1.098, 95% CI [1.075, 1.122] p = 5.5 × 10−18) in the multi-ancestry analysis. Zinc, vitamin B12, retinol, and alpha tocopherol showed nominal associations. Vitamin C, D, K1, B6, beta- and gamma-tocopherol, magnesium, iron, copper, selenium, carotene, and folate showed no significant effects on T1D risk. For the multi-ancestry analysis, we had sufficient power to detect ORs for T1D larger than 1.065. Conclusions: Higher serum potassium levels were associated with increased T1D risk in our MR study, though supporting observational evidence is currently limited. Other micronutrients are unlikely to have large effects on T1D.


  • Association of IGF-1 Levels With Height From Childhood to Adulthood: An Observational and Mendelian Randomization Study

    by Benjamin De La Barrera, Samuel De La Barrera, Isabel Gamache, Soren Harnois-Leblanc, Kaossarath Fagbemi, Ken K Ong, Despoina Manousaki

    Context: Growth hormone therapy, which increases circulating levels of insulin-like growth factor 1 (IGF-1), effectively enhances adult height in children with idiopathic short stature, although with varying responses. Objective: To explore the question whether normal IGF-1 variation within a population is causally associated with height across childhood and in adulthood. Methods: We used two-sample Mendelian randomization (MR) to assess the causal effect of serum IGF-1 on adult height. Genetic instruments for IGF-1 were derived from a UK Biobank genome-wide association study (GWAS), and their effects on adult height were identified in the GIANT Consortium GWAS, excluding UK Biobank (Non-Hispanic White: N = 1 176 465; African descent: N = 168 191; South Asian: N = 49 032; East Asian: N = 361 369; Hispanic: N = 58 709). Using the Avon Longitudinal Study of Parents and Children (ALSPAC), we investigated cross-sectional and longitudinal associations between measured IGF-1 levels at ages 7 to 11 years or a genetic risk score (GRS) for IGF-1, with repeated height measurements at ages 7 to 17 years, adjusting for sex, body mass index (BMI), and pubertal stage. Results: Inverse-variance weighted MR showed that a 1 SD increase in IGF-1 confers 0.09 SD taller adult height, which persisted after adjusting for childhood BMI. In ALSPAC, both measured IGF-1 levels at ages 7 to 8 years and IGF-1 GRS were positively associated with height at ages 7 to 17 years at both cross-sectional and longitudinal analyses. Conclusion: Our findings suggest that IGF-1 normal variation has small effects on height in childhood and on final adult height.


  • Metabolome-Wide Mendelian Randomization and Observational Study Reveal Causal Links Between Circulating Metabolites and Youth-Onset Type 2 Diabetes

    by Kaossarath Fagbemi, Raphael Avocegamou, Nahid Yazdanpanah, Mojgan Yazdanpanah, Basile Jumentier, Isabel Gamache, Despoina Manousaki

    Despite the increasing prevalence of type 2 diabetes in youth, its causal associations with circulating biomarkers remain elusive. We first aimed to identify circulating metabolites causally linked to youth-onset type 2 diabetes using Mendelian randomization (MR). By analyzing 675 metabolites from large metabolomic European genome-wide association studies (GWAS) and data on youth type 2 diabetes from the multiancestry Progress in Diabetes Genetics in Youth (ProDiGY) consortium, we identified 34 candidate metabolites. Among these, phosphatidylcholine (pc) ae C42:3 and propionylcarnitine provided the strongest evidence of association with youth-onset type 2 diabetes, based also on positive genetic colocalization and sensitivity analyses accounting for adiposity. Among the 34 candidate metabolites, 23 were retained following colocalization and a replication MR using independent metabolomic GWAS and testing effects on adult type 2 diabetes. Furthermore, we validated associations of six of these metabolites with glucose metabolism–related traits in an observational study in the Avon Longitudinal Study of Parents and Children (ALSPAC). Notably, pc ae C42:3 levels at age 7 years were linked to dysglycemia and insulin resistance in adolescence. These findings underscore the dynamic role of metabolites in glucose metabolism in childhood, offering insights for future screening and treatment strategies. Article Highlights: Metabolism is key in the pathogenesis of type 2 diabetes in both children and adults, and large-scale metabolomic studies offer a unique source for discovery of biomarkers for these conditions. Leveraging human genetics, we explored whether altered levels of circulating metabolites in the blood are causally linked to type 2 diabetes in youth across different ancestries. Our Mendelian randomization analysis identified causal associations for 34 metabolites, and, among these, Mendelian randomization replication and colocalization prioritized 23 metabolites. Observational evidence from the Avon Longitudinal Study of Parents and Children (ALSPAC) study validated effects on glucose homeostasis for six of these metabolites, among which phosphatidylcholine ae C42:3 emerged as the most promising biomarker. These findings highlight the role of metabolism in glucose homeostasis pathophysiology in youth.


  • Open Access

    Metabolome-wide Mendelian randomisation reveals causal links between circulating metabolites and type 1 diabetes

    by Basile Jumentier, Isabel Gamache, Dominika A. Michalek, Wei-Min Chen, Suna Onengut-Gumuscu, Stephen S. Rich, Constantin Polychronakos, Despoina Manousaki